In vivo determination of efficacy of pyrazoloquinolinones at the benzodiazepine receptor.
The pyrazoloquinolinones CGS 9896, CGS 9895 and CGS 8216 potently displace the benzodiazepines from their CNS binding site in vitro but have been reported to display agonist, partial agonist and antagonist activity respectively in a number of in vivo tests in rats. We found CGS 9896 to have only weak antipentylenetetrazole activity in mice at doses which produced near maximal displacement of [3H]flunitrazepam in vivo and were not able to detect any antipentylenetetrazole activity of CGS 9895. However, CGS 9895 blocked the anticonvulsant effect of diazepam at doses closely related to those which inhibited the in vivo binding of [3H]flunitrazepam and CGS 9896 also showed some reversal of the antipentylenetetrazole action of diazepam. This is consistent with the notion that CGS 9896 is a partial agonist and CGS 9895 an antagonist at the benzodiazepine receptor.
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D003292:Convulsants / Q000494:pharmacology*; D003975:Diazepam / Q000037:antagonists & inhibitors; D005445:Flunitrazepam / Q000378:metabolism; D008297:Male; D051379:Mice; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors*; D011720:Pyrazoles / Q000494:pharmacology*; D011963:Receptors, GABA-A / Q000187:drug effects*
D003292:Convulsants; D011720:Pyrazoles; D011963:Receptors, GABA-A; D005445:Flunitrazepam; C034704:2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one; C039232:2,5-dihydro-2-(4-methoxyphenyl)-3H-pyrazolo(4,3-c)quinolin-3-one; C033830:2-phenylpyrazolo(4,3-c)quinolin-3(5H)-one; D003975:Diazepam; D010433:Pentylenetetrazole